Multi-modal strategies for overcoming tumor drug resistance: Hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Inefficiency in systemic drug delivery and tumor residence as well microenvironmental selection pressures contribute to the development of multidrug resistance (MDR) in cancer. Characteristics of MDR include abnormal vasculature, regions of hypoxia, up-regulation of ABC-transporters, aerobic glycolysis, and an elevated apoptotic threshold. Nano-sized delivery vehicles are ideal for treating MDR cancer as they can improve the therapeutic index of drugs and they can be engineered to achieve multifunctional parameters. The multifunctional ability of nanocarriers makes them more adept at treating heterogeneous tumor mass than traditional chemotherapy. Nanocarriers also have preferential tumor accumulation via the EPR effect; this accumulation can be further enhanced by actively targeting the biological profile of MDR cells. Perhaps the most significant benefit of using nanocarrier drug delivery to treat MDR cancer is that nanocarrier delivery diverts the effects of ABC-transporter mediated drug efflux; which is the primary mechanism of MDR. This review discusses the capabilities, applications, and examples of multifunctional nanocarriers for the treatment of MDR. This review emphasizes multifunctional nanocarriers that enhance drug delivery efficiency, the application of RNAi, modulation of the tumor apoptotic threshold, and physical approaches to overcome MDR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting HIF-1 for cancer therapy
Semenza, G. L. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1187 · Cited by 6,717
Multidrug resistance in cancer: role of ATP–dependent transporters
Gottesman, M. M., Fojo, T., & Bates, S. E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc706 · Cited by 5,536
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177 · cited 6×
“Hypoxia-inducible factor (HIF)-1 alpha directly enhances the transcriptional activity of stem cell factor (SCF) in response to hypoxia and epidermal growth factor (EGF).”
BackgroundInfluentialNanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · cited 1×
“A key benefit of using nanocarriers for the treatment of MDR is that nanoparticles have been demonstrated to bypass efflux by ABC transporters as they are internalized via non-specific endocytosis (or facilitated uptake for targeted nanocarriers) and result in higher intracellular accumulation [41].”
BackgroundCancer cell metabolism: warburg and beyond
Hsu, P. P., & Sabatini, D. M. (2008) · Cell · doi:10.1016/j.cell.2008.08.021 · Cited by 2,452
Drug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116 · cited 2×
“activity of HIF, which activates MDR proteins and mechanisms [4, 9, 14, 17, 20-24].”
BackgroundNanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029 · cited 2×
“The nanoscale behaviour of the platform material is very different from the properties of the bulk platform material due to the large surface area to volume ratio that characterizes nanoparticles [32-35].”
BackgroundNoninvasive detection of clinically occult lymph-node metastases in prostate cancer
Harisinghani, M. G., Barentsz, J., Hahn, P. F., Deserno, W. M., Tabatabaei, S., van de Kaa, C. H., de la Rosette, J., & Weissleder, R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022749 · Cited by 1,971
Reactive oxygen species in cancer cells: Live by the sword, die by the sword
Schumacker, P. T. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.015 · Cited by 1,242
Brahimi-Horn, M. C., Chiche, J., & Pouysségur, J. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0281-3 · Cited by 765 · cited 3×
“The vast array of HIF targets include genes involved in invasion, proliferation, metabolism, and drug resistance [9-17].”
Background
Cited by
Nanomedicine therapeutic approaches to overcome cancer drug resistance
Markman, J. L., Rekechenetskiy, A., Holler, E., & Ljubimova, J. Y. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.019 · Cited by 733
“These hypoxic cells often revert to aerobic metabolism for the production of ATP (the Warburg effect) [73,74] to maintain enough energy to continue to thrive.”
BackgroundChen, Z., Shi, T., Zhang, L., Zhu, P., Deng, M., Huang, C., Hu, T., Jiang, L., & Li, J. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.010 · Cited by 729
Shahbazi, M.-A., Faghfouri, L., Ferreira, M. P. A., Figueiredo, P., Maleki, H., Sefat, F., Hirvonen, J., & Santos, H. A. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00283a · Cited by 523
He, Q., & Shi, J. (2014) · Advanced Materials · doi:10.1002/adma.201303123 · Cited by 482
Cancer Stem Cells and Drug Resistance: The Potential of Nanomedicine
Vinogradov, S., & Wei, X. (2012) · Nanomedicine · doi:10.2217/nnm.12.22 · Cited by 474
Metadata
- Authors
- Milane, L., Ganesh, S., Shah, S., Duan, Z.-F., & Amiji, M.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2011-10
- Volume
- 155
- Issue
- 2
- Pages
- 237-247
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2071860668
- Cited by
- 128
- References
- 14
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multi-modal strategies for overcoming tumor drug resistance: Hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology. https://app.cochat.ai/papers/10.1016/j.jconrel.2011.03.032
- The paper
- Milane, L., Ganesh, S., Shah, S., Duan, Z.-F., & Amiji, M. (2011). Multi-modal strategies for overcoming tumor drug resistance: Hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2011.03.032
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.